Skip to main content
. 2001 Feb 15;29(4):872–879. doi: 10.1093/nar/29.4.872

Figure 2.

Figure 2

Complementation of a CHO 43-3B extract with ERCC1 protein. (A) Extract (60 µg protein) derived from the CHO 43-3B ERCC1 mutant cell line was incubated with plasmid DNA molecules containing a single cisplatin lesion (lane 1) and various amounts of recombinant ERCC1 and/or recombinant XPF (lanes 2–6). Reactions in lanes 2–5 received 300, 262.5, 150 and 37.5 ng of ERCC1, respectively. Reactions in lanes 3–6 received 37.5, 150, 262.5 and 300 ng of XPF, respectively. Lane 7 is a control reaction with 18.5 ng of the ERCC1–XPF complex produced in E.coli with a dicistronic vector encoding both subunits. Excised oligonucleotides are indicated by the bracket on the left. (B) The activity of Δ88ERCC1 was compared to the activity of full-length ERCC1. Reactions in lanes 2–4 received 38, 150 and 300 ng of rERCC1, respectively, and in lanes 5–7 they received 38, 150 and 300 ng of Δ88ERCC1, respectively. (C) Quantification of the relative complementation levels reached with ERCC1 (dotted line) and Δ88ERCC1 (solid line).